Myopia control refers to treatments specifically designed to slow the progression of nearsightedness in children. This matters because myopia typically worsens throughout childhood and adolescence. The higher myopia increases the risk of serious eye conditions later in life, including retinal detachment, glaucoma, cataracts, and myopic macular degeneration. Children whose myopia is controlled end up with lower final prescriptions, reducing these lifetime risks. Treatment options include specialized contact lenses, atropine eye drops, and orthokeratology. Starting myopia control early, when progression is fastest, provides the greatest benefit for long-term eye health.

CooperVision MiSight 1 day contact lenses use a dual-focus design that provides clear central vision while creating peripheral myopic defocus. This optical design signals the eye to slow its abnormal growth. MiSight lenses are FDA-approved specifically for myopia control in children ages 8-12 and are worn during the day like regular soft contact lenses, then discarded nightly. Clinical studies show MiSight reduces myopia progression by an average of 59% compared to regular single-vision correction. Our optometrists determine if your child is a good candidate based on their age, prescription, and ability to handle contact lens care.

Myopia control is most effective when started early, typically between ages 6-12, when eye growth and myopia progression are most rapid. Children who become nearsighted before age 8 often experience faster progression and benefit most from early intervention. However, treatment can still provide benefits for teenagers whose myopia continues to worsen. The key indicator for starting treatment is documented myopia progression over time rather than a specific age. If your child’s prescription has increased by 0.50 diopters or more per year, they’re a strong candidate for myopia control intervention.

Myopia control is most effective when started early, typically between ages 6-12, when eye growth and myopia progression are most rapid. Children who become nearsighted before age 8 often experience faster progression and benefit most from early intervention. However, treatment can still provide benefits for teenagers whose myopia continues to worsen. The key indicator for starting treatment is documented myopia progression over time rather than a specific age. If your child’s prescription has increased by 0.50 diopters or more per year, they’re a strong candidate for myopia control intervention.

Yes, myopia control treatments have established safety profiles appropriate for pediatric use. MiSight and other specialized contact lenses carry risks similar to any soft contact lens, managed through proper hygiene and regular eye care. Low-dose atropine drops have been used safely in children for decades with minimal side effects at therapeutic concentrations for myopia control. Orthokeratology requires careful fitting and monitoring but has a strong safety record when properly managed. All myopia control options involve regular follow-up appointments to monitor effectiveness and address any concerns. Our team thoroughly discusses benefits and risks before recommending treatment.

Research consistently shows that children who spend more time outdoors have lower rates of myopia development and slower progression. Studies suggest that at least two hours of daily outdoor time provides protective benefits. The mechanism appears related to bright light exposure triggering dopamine release in the retina, which helps regulate eye growth. Outdoor time is most effective for preventing myopia onset in children who aren’t yet nearsighted. For children already myopic, outdoor activity complements other control treatments but may not slow progression as effectively on its own. Encourage outdoor play as part of a comprehensive approach to your child’s visual health.